It is time to rethink the dual antiplatelet therapy indication in revascularization surgery

Abstract

Dual antiplatelet therapy (DAP) in coronary artery bypass grafting (CABG) surgery in the context of stable ischemic heart disease is in increasing development, although ACC/AHA and European guidelines do not strongly recommend it and have different criteria. Saphenous vein
graft failure in the first month in the postoperative period of surgery is not only frequent but serious. The balance between thrombotic and hemorrhagic risk must be obtained in these patients with the objective of identifying those who will benefit with DAP and those who will not.
In this opinion paper the newest evidence is shown for considering DAP for the postoperative period in CABG.